HARVARD BIOSCIENCE INC

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

HBIO$9.09+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenues	$20,450	$23,097	$42,224	$47,609
Cost of revenues	8,917	9,879	18,507	19,619
Gross profit	11,533	13,218	23,717	27,990
Sales and marketing expenses	4,539	5,395	9,510	11,299
General and administrative expenses	4,262	5,686	9,447	11,649
Research and development expenses	2,189	2,626	4,510	5,511
Amortization of acquired intangible assets	1,162	1,331	2,322	2,664
Goodwill impairment - Note 4	-	-	47,951	-
Other operating expenses - Note 1	200	249	464	1,215
Total operating expenses	12,352	15,287	74,204	32,338
Operating loss	(819)	(2,069)	(50,487)	(4,348)
Other expense:
Interest expense	(791)	(749)	(1,593)	(1,500)
Loss on equity securities - Note 6	-	(281)	-	(1,593)
Other expense, net	(644)	(181)	(968)	(323)
Total other expense	(1,435)	(1,211)	(2,561)	(3,416)
Loss before income taxes	(2,254)	(3,280)	(53,048)	(7,764)
Income tax expense (benefit)	28	(353)	(426)	(143)
Net loss	$(2,282)	$(2,927)	$(52,622)	$(7,621)
Loss per share:
Basic and diluted loss per share	$(0.05)	$(0.07)	$(1.19)	$(0.18)
Weighted-average common shares:
Basic and diluted	44,303	43,486	44,200	43,443

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.